Worsening injection site reactions with continued use of etanercept.
We report the case of a patient with persistent and worsening injection site reactions associated with subcutaneous etanercept therapy. Injection site reactions are well documented to occur early in therapy; however they typically decrease in frequency over time. This patient developed early injection site reactions that have persisted and worsened into his tenth month of treatment with etanercept.
Edwards
Kimberly R
KR
Department of Dermatology, Geisinger Medical Center, 100 N. Academy Avenue, Danville, PA 17821, USA.
Mowad
Christen M
CM
Tyler
William B
WB
D000005:Abdomen; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D004342:Drug Hypersensitivity / Q000473:pathology; D004890:Erythema / Q000139:chemically induced* / Q000473:pathology; D000068800:Etanercept; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000139:chemically induced / Q000473:pathology; D007074:Immunoglobulin G / Q000008:administration & dosage* / Q000009:adverse effects*; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage*
D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept